Biocon Biologics launches arthritis drug in United States

Bengaluru: Biocon Biologics has launched Hulia (adalimumab-fkjp) injection, a biosimilar to Humira, in the US, after five years of experience in Europe and two years in Canada. Adalimumab is a monoclonal antibody used to treat rheumatoid arthritis and psoriatic arthritisamong other debilitating diseases. Biocon Biologics has secured multiple biosimilar approvals in the US, Europe, and over 100 countries. “This launch builds on our strong presence in oncology and diabetes,” said Shreehas Tambe, CEO & MD of Biocon Biologics. tnn